Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Trimetazidine decreases Ca2+ response to thapsigargin in differentiated and undifferentiated human HL-60 cells.

× No keyword cloud information.

14 in total

1. Effect of ATP on different Ca2+ channels in PC12 pheochromocytoma cells.

Authors: E I Astashkin; E A Shirokova; I A Grivennikov; S V Glezer; S V Grachev
Journal: Dokl Biol Sci Date: 2000 Jul-Aug

Review 2. Effectors of fatty acid oxidation reduction: promising new anti-ischaemic agents.

Authors: Alain Grynberg
Journal: Curr Pharm Des Date: 2005 Impact factor: 3.116

Review 3. Calcium signalling: past, present and future.

Authors: Ole H Petersen; Marek Michalak; Alexei Verkhratsky
Journal: Cell Calcium Date: 2005 Sep-Oct Impact factor: 6.817

Review 4. Cellular calcium in health and disease.

Authors: F C Mooren; R K Kinne
Journal: Biochim Biophys Acta Date: 1998-03-05

Review 5. The cell cycle: a new entry in the field of Ca2+ signaling.

Authors: L Santella; E Ercolano; G A Nusco
Journal: Cell Mol Life Sci Date: 2005-11 Impact factor: 9.261

6. Lineage-specific modulation of calcium pump expression during myeloid differentiation.

Authors: S Launay; M Giannì; T Kovàcs; R Bredoux; A Bruel; P Gélébart; F Zassadowski; C Chomienne; J Enouf; B Papp
Journal: Blood Date: 1999-06-15 Impact factor: 22.113

Review 7. Partial fatty acid oxidation inhibitors for stable angina.

Authors: William C Stanley
Journal: Expert Opin Investig Drugs Date: 2002-05 Impact factor: 6.206

Review 8. Glucose and glycogen utilisation in myocardial ischemia--changes in metabolism and consequences for the myocyte.

Authors: L M King; L H Opie
Journal: Mol Cell Biochem Date: 1998-03 Impact factor: 3.396

Review 9. Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine.

Authors: William C Stanley; Mario Marzilli
Journal: Fundam Clin Pharmacol Date: 2003-04 Impact factor: 2.748

10. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.

Authors: P F Kantor; A Lucien; R Kozak; G D Lopaschuk
Journal: Circ Res Date: 2000-03-17 Impact factor: 17.367

1 in total

1. Trimetazidine selectively inhibits SOC channels in plasma membranes of human HL-60 cells and does not affect the intracellular Ca2+ stores.

Authors: E I Astashkin; M G Glezer; S V Grachev
Journal: Dokl Biol Sci Date: 2009 Jan-Feb

1 in total